Sector News

Stada agrees to compromise with activist investor on board reshuffle

May 13, 2016
Life sciences

German generic drugmaker Stada has agreed to a shareholder vote on proposed board changes after an activist investor had asked for a thorough overhaul, the company said on Friday.

Active Ownership Capital will now seek to replace three instead of five of Stada’s nine supervisory board members at its annual general meeting on June 9, and it is no longer asking for the removal of board Chairman Martin Abend.

Stada said in a statement it was agreeing to the compromise to avoid a pricey legal battle as well as the need to call an extraordinary meeting of shareholders.

Shares in Stada have surged about 11 percent this month on speculation that Active Ownership’s campaign could lead to the sale or break up of the company.

The Luxembourg-based investor, which has a 5 percent stake in the company, has said its push for a shareholder vote on the supervisory board is to add international healthcare expertise to help Stada realise its potential.

Active Ownership wants Klaus-Joachim Krauth, the former finance chief of Hexal and Athos; Ulrich Wandschneider, who until recently was chief executive of hospitals chain Asklepios Kliniken; and Active Ownership founding partner Klaus Roehrig on the supervisory board.

They would replace Eckhard Brueggemann, Arnold Hertzsch and Constantin Meyer.

By Arno Schuetze, Alexander Huebner and Maria Sheahan

Source: Reuters

comments closed

Related News

November 19, 2022

Sequana announces results from study of direct sodium removal

Life sciences

Sequana, a company focusing on liver disease, heart failure and cancer has announced positive top-line results from SAHARA – the phase 2a study using its first-generation direct sodium removal (DSR) product, DSR 1.0. Data from ten evaluable diuretic-resistant heart failure patients confirmed long-lasting clinical benefits.

November 19, 2022

Bristol Myers Squibb opens 125-acre biologics campus in Dublin

Life sciences

Bristol Myers Squibb has officially opened its Cruiserath Biologics site in Dublin. The site, which represents a $1bn investment – was officially opened by the company’s chief executive officer, Giovanni Caforio, who arrived from New York, and site general manager Pádraig Keane.

November 19, 2022

Pharma must stay the course on Twitter as docs are not abandoning the platform yet: Report

Life sciences

Like it or loathe it, and whatever its new direction, Twitter is still a powerful platform for doctors, and pharma should not abandon the troubled social media site yet, according to a new report from healthcare consultants at ZoomRx.